Spatial transcriptomics has become a standard lens on tumor biology in pharma, revealing how gene programs organize across a tumor and change under treatment.
Tissue architecture used to be background information. Now it is a data type pharma teams use to find targets, read the tumor microenvironment, and build the next generation of biomarkers.
A target that looks promising in a dissociated cell suspension can behave differently once it is put back in the tissue that determines whether it actually matters.
The best targets are often defined by where they act, not only whether they are expressed. Spatial data is what finally lets a discovery team see that distinction.
A cascade of high-profile drug recalls and evolving FDA and EMA guidance have pushed nitrosamine risk assessment from a late-stage afterthought to an early-development priority
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.